B. Riley analyst Neil Chatterji raised the firm’s price target on Augmedix (AUGX) to $5 from $4 and keeps a Buy rating on the shares. The company announced a "significant" collaboration with and strategic investment from HCA Healthcare (HCA) to accelerate the development of artificial intelligence-powered ambient documentation products for complex acute care settings, the analyst tells investors in a research note. Along with the partnership, Augmedix raised $12M in equity from HCA and Redmile Group, which management believes will add enough capital to reach cash flow breakeven and sustainability exiting 2024, the firm points out.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AUGX:
- Augmedix Blasts Up on New Partnership
- Augmedix spikes 85% in pre-market after announcing pact with HCA Healthcare
- Augmedix partners with HCA Healthcare for AI-enabled documentation
- Augmedix Secures Strategic Financing from HCA Healthcare and Redmile Group
- Augmedix Announces Partnership with HCA Healthcare to Accelerate the Development of AI-enabled Ambient Documentation